Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous denosumab in multiple myeloma after deep response
ChiCTR2300071406Phase 4Completed
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab in multiple myeloma (MM), sponsored by Beijing Jishuitan Hospital. Primary endpoint: Progression-free survival. Started Mar 2023; status: completed.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2300071406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071406.